

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection All of the codes used in this study are available at <https://github.com/yachielab/QUEEN/>. All of the data collection and production procedures are provided by Jupyter Notebook version 6.4.4 and Google Colaboratory (see Supplementary Table 1).

Data analysis All of the codes used in this study are available at <https://github.com/yachielab/QUEEN/>. All of the data collection and production procedures are provided by Jupyter Notebook version 6.4.4 and Google Colaboratory (see Supplementary Table 1).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The gbk files for pLV-eGFP, pCMV-ABE7.10, pcDNA3.1_pCMV-nCas-PmCDA1-ugi pH1-gRNA(HPRT), pCMV-BE4max and pCMV-ABEmax were obtained from Addgene (Plasmid IDs: 36083, 102919, 79620, 112903, and 112905, respectively). The sequence file for pLV-SIN-CMV-Puro was obtained from Takara Bio, Inc. (Japan, https://catalog.takara-bio.co.jp/DNA_seq/pLVSIN-CMV_pur.zip). The gbk file for pRS112 and pUC-optimized-PmCDA1-ugi encoding the codon-optimized PmCDA1-UGI was created using Benchling. Some detail sequence feature annotations of input files were added manually before using them for the demonstration (the modified files are available at https://github.com/yachielab/QUEEN/tree/master/demo/sakata_et_al_2020). The gbk file used for the simulation of the Boolean logic LUT circuit

was downloaded from Addgene (Plasmid ID 87554), to which sequence feature annotations for the site-specific recombination sites were added manually before the demonstration (the modified file is available at https://github.com/yachielab/QUEEN/tree/master/demo/Weinberg_et_al_2017).

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

- Sample size n/a. This study demonstrates a new semantic framework for DNA construction and does not include any hypotheses.
- Data exclusions n/a. This study demonstrates a new semantic framework for DNA construction and does not include any hypotheses.
- Replication n/a. This study demonstrates a new semantic framework for DNA construction and does not include any hypotheses.
- Randomization n/a. This study demonstrates a new semantic framework for DNA construction and does not include any hypotheses.
- Blinding n/a. This study demonstrates a new semantic framework for DNA construction and does not include any hypotheses.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

- n/a Involved in the study
- Antibodies
- Eukaryotic cell lines
- Palaeontology and archaeology
- Animals and other organisms
- Human research participants
- Clinical data
- Dual use research of concern

Methods

- n/a Involved in the study
- ChIP-seq
- Flow cytometry
- MRI-based neuroimaging